Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAUN15)

Drug Name
Carlumab Drug Info
Synonyms CCL-2; CNTO-888; Anti-MCP1 monoclonal antibodies, Centocor; CCL2 monoclonal antibody (infusion, cancer), Centocor
Indication
Disease Entry ICD 11 Status REF
Pulmonary fibrosis CB03.4 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMAUN15

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Monocyte chemotactic and activating factor (CCL2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bindarit DMS2GA1 Nephritis GB40 Phase 3 [3]
NOX-E36 DMHG3UR Diabetic complication 5A2Y Phase 2 [4]
CNTO888 DMUBP0V Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
ABN-912 DMADKHB Asthma CA23 Discontinued in Phase 1 [6]
MCP-1 DMYEFKH Rheumatoid arthritis FA20 Preclinical [7]
RS-504393 DMB9IPR Chronic obstructive pulmonary disease CA22 Preclinical [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monocyte chemotactic and activating factor (CCL2) TTNAY0P CCL2_HUMAN Not Available [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 771).
2 Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
3 Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
4 Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923.
5 CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62.
6 A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387-92.
7 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
8 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.